These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 19590589)
1. The role of insulin detemir in overweight type 2 diabetes management. Demssie YN; Younis N; Soran H Vasc Health Risk Manag; 2009; 5(3):553-60. PubMed ID: 19590589 [TBL] [Abstract][Full Text] [Related]
2. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Raslova K Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842 [TBL] [Abstract][Full Text] [Related]
3. Differences between long-acting insulins for the treatment of type 2 diabetes. Jensen MG; Hansen M; Brock B; Rungby J Expert Opin Pharmacother; 2010 Aug; 11(12):2027-35. PubMed ID: 20642370 [TBL] [Abstract][Full Text] [Related]
4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Hollander P; Cooper J; Bregnhøj J; Pedersen CB Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786 [TBL] [Abstract][Full Text] [Related]
5. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419 [TBL] [Abstract][Full Text] [Related]
6. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040 [TBL] [Abstract][Full Text] [Related]
7. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668 [TBL] [Abstract][Full Text] [Related]
8. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. Kabadi UM Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012 [TBL] [Abstract][Full Text] [Related]
9. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S; Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776 [TBL] [Abstract][Full Text] [Related]
10. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170 [TBL] [Abstract][Full Text] [Related]
11. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Meneghini LF; Dornhorst A; Sreenan S; Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426 [TBL] [Abstract][Full Text] [Related]
12. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Heller S; Koenen C; Bode B Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879 [TBL] [Abstract][Full Text] [Related]
13. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016 [TBL] [Abstract][Full Text] [Related]
14. Treat-to-target trials: uses, interpretation and review of concepts. Garber AJ Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598 [TBL] [Abstract][Full Text] [Related]
15. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668 [TBL] [Abstract][Full Text] [Related]
16. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Davies MJ; Derezinski T; Pedersen CB; Clauson P Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200 [TBL] [Abstract][Full Text] [Related]
17. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. Garber AJ; Clauson P; Pedersen CB; Kølendorf K J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896 [TBL] [Abstract][Full Text] [Related]
18. The use of insulin analogues in pregnancy. Lambert K; Holt RI Diabetes Obes Metab; 2013 Oct; 15(10):888-900. PubMed ID: 23489521 [TBL] [Abstract][Full Text] [Related]
19. Insulin detemir in the treatment of type 1 and type 2 diabetes. Philips JC; Scheen A Vasc Health Risk Manag; 2006; 2(3):277-83. PubMed ID: 17326333 [TBL] [Abstract][Full Text] [Related]
20. Basal insulin analogues--a review of recent data on efficacy and safety. John M J Assoc Physicians India; 2011 Apr; 59 Suppl():25-8. PubMed ID: 21818995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]